Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
According to Clarivate epidemiology, cognitive dysfunction (e.g., impaired attention / vigilance, memory, executive function) occurs in the vast majority of diagnosed schizophrenia patients and has…
Clarivate Epidemiology’s coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide…
Clarivate Epidemiology’s coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Parkinson’s disease patient populations covering 171 countries and…
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta—which launched in 2011—the…